Managed Healthcare Executive September 11, 2021
In an interview with MHE, SVP Savitha Vivian said the biosimilars to Humira and Novolog that are expected to be on the market in the next few years could have the kind of impact that proponents of biosimilars have been hoping for.
The FDA has approved 30 biosimilars and 21 have been launched. But it won’t be till biosimilars for some of the more widely prescribed biologics are on the market before biosimilars really start to have a major impact on American healthcare and its cost, according to a top-ranking executive at OptumRx.
“We’re still a few years away from the point at which the most widely-utilized … products in the U.S. today will be available as biosimilars,” Savitha Vivian,...
Today's Sponsors
Today's Sponsor